JP Morgan Reinstates Overweight on Stoke Therapeutics, Announces $40 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 67.5%

Neg 0% Neu 67.5% Pos 0%

JP Morgan analyst Jessica Fye reinstates Stoke Therapeutics (NASDAQ:STOK) with a Overweight and announces $40 price target.